Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade.

Moesta AK, Cooke K, Piasecki J, Mitchell P, Rottman JB, Fitzgerald K, Zhan J, Yang B, Le T, Belmontes B, Ikotun OF, Merriam K, Glaus C, Ganley K, Cordover DH, Boden AM, Ponce R, Beers C, Beltran PJ.

Clin Cancer Res. 2017 Oct 15;23(20):6190-6202. doi: 10.1158/1078-0432.CCR-17-0681. Epub 2017 Jul 13.

PMID:
28706012
2.

Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.

Moody G, Belmontes B, Masterman S, Wang W, King C, Murawsky C, Tsuruda T, Liu S, Radinsky R, Beltran PJ.

Int J Cancer. 2016 Sep 15;139(6):1340-9. doi: 10.1002/ijc.30180. Epub 2016 May 31.

3.

Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St Jean DJ Jr, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS.

ACS Med Chem Lett. 2015 Jul 27;6(9):987-92. doi: 10.1021/acsmedchemlett.5b00193. eCollection 2015 Sep 10.

4.

Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, Olivieri PR, Schenkel LB, Vaida KR, Andrews P, Bak A, Be X, Beltran PJ, Bush TL, Chaves MK, Chung G, Dai Y, Eden P, Hanestad K, Huang L, Lin MH, Tang J, Ziegler B, Radinsky R, Kendall R, Patel VF, Payton M.

J Med Chem. 2015 Jul 9;58(13):5189-207. doi: 10.1021/acs.jmedchem.5b00183. Epub 2015 May 31.

PMID:
25970324
5.

Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).

Smith AL, Andrews KL, Beckmann H, Bellon SF, Beltran PJ, Booker S, Chen H, Chung YA, D'Angelo ND, Dao J, Dellamaggiore KR, Jaeckel P, Kendall R, Labitzke K, Long AM, Materna-Reichelt S, Mitchell P, Norman MH, Powers D, Rose M, Shaffer PL, Wu MM, Lipford JR.

J Med Chem. 2015 Feb 12;58(3):1426-41. doi: 10.1021/jm5017494. Epub 2015 Jan 14.

PMID:
25587754
6.

A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.

Fahrenholtz CD, Greene AM, Beltran PJ, Burnstein KL.

Oncotarget. 2014 Oct 15;5(19):9007-21.

7.

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE.

Clin Cancer Res. 2014 Jun 1;20(11):2947-58. doi: 10.1158/1078-0432.CCR-13-3448. Epub 2014 Apr 11.

8.

IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.

Moody G, Beltran PJ, Mitchell P, Cajulis E, Chung YA, Hwang D, Kendall R, Radinsky R, Cohen P, Calzone FJ.

J Endocrinol. 2014 Mar 17;221(1):145-55. doi: 10.1530/JOE-13-0306. Print 2014 Apr.

9.

Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts.

Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P, Aronson WJ.

Int J Mol Sci. 2013 Jul 3;14(7):13782-95. doi: 10.3390/ijms140713782.

10.

Epitope-specific mechanisms of IGF1R inhibition by ganitumab.

Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R, Beltran PJ.

PLoS One. 2013;8(2):e55135. doi: 10.1371/journal.pone.0055135. Epub 2013 Feb 1.

11.

Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.

Fahrenholtz CD, Beltran PJ, Burnstein KL.

Mol Cancer Ther. 2013 Apr;12(4):394-404. doi: 10.1158/1535-7163.MCT-12-0648. Epub 2013 Jan 24.

12.

Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.

Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ.

Mol Cancer Ther. 2012 Jul;11(7):1539-46. doi: 10.1158/1535-7163.MCT-11-1003. Epub 2012 May 4.

13.

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.

Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):644-54. doi: 10.1124/jpet.110.178400. Epub 2011 Mar 8.

14.

Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.

Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2010 Aug;9(8):2399-410. doi: 10.1158/1535-7163.MCT-10-0181. Epub 2010 Jul 27.

15.

Dimerization of tyrosine phosphatase PTPRO decreases its activity and ability to inactivate TrkC.

Hower AE, Beltran PJ, Bixby JL.

J Neurochem. 2009 Sep;110(5):1635-47. doi: 10.1111/j.1471-4159.2009.06261.x. Epub 2009 Jul 1.

16.

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.

Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ.

Mol Cancer Ther. 2009 May;8(5):1095-105. doi: 10.1158/1535-7163.MCT-08-1171. Epub 2009 Apr 14.

17.
18.

Receptor protein tyrosine phosphatases as mediators of cellular adhesion.

Beltran PJ, Bixby JL.

Front Biosci. 2003 Jan 1;8:d87-99. Review.

PMID:
12456340
19.

Intratumoral heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma.

Yoon SS, Fidler IJ, Beltran PJ, Bucana CD, Wang YF, Fan D.

Melanoma Res. 1997 Aug;7(4):275-87.

PMID:
9293477
20.
21.

Bcl-2 protects cells from cytokine-induced nitric-oxide-dependent apoptosis.

Xie K, Huang S, Wang Y, Beltran PJ, Juang SH, Dong Z, Reed JC, McDonnell TJ, McConkey DJ, Fidler IJ.

Cancer Immunol Immunother. 1996 Oct;43(2):109-15.

PMID:
8954145
22.
23.

Transcriptional induction of the melanocyte-stimulating hormone receptor in brain metastases of murine K-1735 melanoma.

Radinsky R, Beltran PJ, Tsan R, Zhang R, Cone RD, Fidler IJ.

Cancer Res. 1995 Jan 1;55(1):141-8.

Supplemental Content

Loading ...
Support Center